LGND
NASDAQLigand Pharmaceuticals Incorporated
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$304.21+1.47 (+0.49%)
01:30 PM07:45 PM
News · 26 weeks76-56%
2026-01-252026-07-19
Mix4590d
- Insider17(38%)
- SEC Filings14(31%)
- Other7(16%)
- Offering4(9%)
- Earnings2(4%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form S-8 filed by Ligand Pharmaceuticals IncorporatedS-8 - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- ANALYSTCitigroup resumed coverage on Ligand Pharma with a new price targetCitigroup resumed coverage of Ligand Pharma with a rating of Buy and set a new price target of $387.00
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRXOMA Royalty Announces Closing of Its Acquisition by LigandEMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has completed its previously announced acquisition of XOMA Royalty. Pursuant to the terms of the transaction announced on April 27, 2026, Ligand acquired all of the outstanding shares of XOMA Royalty common stock. XOMA Royalty stockholders received $39.00 in cash per share of XOMA Royalty common stock owned. XOMA Royalty stockholders and equity award holders also received one non-transferable Contingent Value Right ("CVR") per share entitling the holder to receive a portion of 75% of the net proceeds that may result from certain pending liti
- PRLigand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty AssetsAcquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it has completed its acquisition of XOMA Royalty Corporation ("XOMA Royalty"), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million. XOMA Royalty stockholders also received one
- INSIDERCLO & Secretary Reardon Andrew acquired $21,214 worth of shares (132 units at $160.71) as part of a pre-agreed trading plan, exercised 5,000 shares at a strike of $52.27 and sold $1,566,377 worth of shares (5,000 units at $313.28) as part of a pre-agreed trading plan, increasing direct ownership by 0.32% to 41,514 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERChief Financial Officer Espinoza Octavio acquired $2,732 worth of shares (17 units at $160.71), increasing direct ownership by 0.06% to 27,696 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERChief Executive Officer Davis Todd C acquired $21,214 worth of shares (132 units at $160.71), increasing direct ownership by 0.07% to 199,513 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Announces Closing of Convertible Senior Notes OfferingOpportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today that it completed its previously announced offering (the "offering") of 0.00% convertible senior notes due 2031 (the "notes"). The aggregate principal amount of the notes sold in the offering was $700.0 million, which includes the purchase of an additional $75.0 million aggregate principal amount
- PRLigand Announces Pricing of Upsized $625 Million Convertible Senior Notes OfferingOpportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes JUPITER, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Sec
- SECSEC Form 8-K filed by Ligand Pharmaceuticals Incorporated8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes JUPITER, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "
- INSIDERDirector Sabba Stephen L exercised 2,145 shares at a strike of $66.13 and sold $544,830 worth of shares (2,145 units at $254.00) (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Haas Jason exercised 4,000 shares at a strike of $51.56 and sold $1,651,320 worth of shares (6,461 units at $255.58), decreasing direct ownership by 33% to 4,981 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Aryeh Jason was granted 836 shares and sold $1,250,000 worth of shares (5,000 units at $250.00), decreasing direct ownership by 4% to 102,580 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Lamattina John L sold $1,151,774 worth of shares (4,591 units at $250.88), decreasing direct ownership by 15% to 26,969 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- PRLigand Announces 2026 Investor Day in New York CityJUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m. Eastern time at the Harvard Club. The event will include presentations from Ligand's senior management team highlighting the company's strategy, recent investment activity, royalty portfolio, and long-term financial outlook. A live webcast of the event will be accessible through Ligand's Investor Relations website at investor.ligand.com. A detailed agenda, including dial-in information, will be provided closer to the event. About Ligand Ligand is a leading royalty aggregator, partne
- INSIDERDirector Zimmermann Martine was granted 836 shares and covered exercise/tax liability with 182 shares, increasing direct ownership by 15% to 5,097 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Sabba Stephen L was granted 836 shares, increasing direct ownership by 3% to 33,629 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Lamattina John L was granted 836 shares, increasing direct ownership by 3% to 31,560 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Kozarich John W was granted 836 shares, increasing direct ownership by 2% to 42,622 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Haas Jason was granted 836 shares, increasing direct ownership by 13% to 7,442 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Gray Nancy Ryan was granted 836 shares, increasing direct ownership by 10% to 8,930 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
LGND FAQ
6 questionsWhat does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled...Where does LGND stock trade?
Ligand Pharmaceuticals Incorporated (LGND) is listed on NASDAQ.What sector and industry is LGND in?
Ligand Pharmaceuticals Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LGND?
Ligand Pharmaceuticals Incorporated has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-07-21.What companies are similar to LGND?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LGND side-by-side with any of them on Quantisnow.How can I track LGND on Quantisnow?
Quantisnow aggregates Ligand Pharmaceuticals Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LGND to receive live email and push alerts on every new disclosure.